Reform runaway winners in north-east, likely pushing Labour into opposition in Hartlepool, with other losses for Starmer in Chorley, Wigan, Redditch and Tamworth Election 2026 live: latest news updates Full results from England, Scotland and Wales The scale of the electoral challenge facing Labour was laid bare overnight as the party haemorrhaged councillors at the local elections and Reform made ...
Reform runaway winners in north-east, likely pushing Labour into opposition in Hartlepool, with other losses for Starmer in Chorley, Wigan, Redditch and Tamworth Election 2026 live: latest news updates Full results from England, Scotland and Wales The scale of the electoral challenge facing Labour was laid bare overnight as the party haemorrhaged councillors at the local elections and Reform made significant gains. Keir Starmer’s party went into Thursday’s local elections expected to lose up to 1,850 councillors, with senior figures describing the contest as “tough”. Continue reading...
There are scenarios for oil prices based on how long the Iran war lasts, according to Jacky Tang, emerging markets chief investment officer at Deutsche Bank's private banking arm. (Source: Bloomberg)
There are scenarios for oil prices based on how long the Iran war lasts, according to Jacky Tang, emerging markets chief investment officer at Deutsche Bank's private banking arm. (Source: Bloomberg)
Earnings Call Insights: Fox Factory Holding Corp. (FOXF) Q1 2026 Management view "We delivered first quarter revenue of $368.7 million, which was at the high end of our guidance range and adjusted EBITDA of $35.7 million, exceeding the high end of our guidance range." (CEO Michael Dennison) "Phase 1 carryover is flowing through, Phase 2 is on schedule, and we closed the divestiture of our Phoenix,...
Earnings Call Insights: Fox Factory Holding Corp. (FOXF) Q1 2026 Management view "We delivered first quarter revenue of $368.7 million, which was at the high end of our guidance range and adjusted EBITDA of $35.7 million, exceeding the high end of our guidance range." (CEO Michael Dennison) "Phase 1 carryover is flowing through, Phase 2 is on schedule, and we closed the divestiture of our Phoenix, Arizona operations in the quarter as planned." (CEO Dennison) "We are not counting on end market recovery or tariff relief in 2026." (CEO Dennison) "We are confident in delivering approximately $50 million of savings in 2026, $10 million of Phase 1 carryover and approximately $40 million of Phase 2 actions identified and in execution." (CEO Dennison) "PVG delivered net sales of $143.4 million in the first quarter, an increase of 17.4% year-over-year." (CEO Dennison) "AAG delivered net sales of $114.8 million, an increase of 2.6% year-over-year." (CEO Dennison) "In the last 60 days, we have added over 135 new dealers, and we are averaging over 60 new dealers a month as we go forward." (CEO Dennison) "SSG delivered net sales of $110.5 million, a decrease of 8.7% year-over-year." (CEO Dennison) "Total consolidated net sales in the first quarter of fiscal 2026 were $368.7 million, an increase of 3.9% versus the same quarter last year." (Chief Financial Officer Dennis Schemm) Outlook "For the full year 2026, we continue to expect net sales in the range of $1.328 billion to $1.416 billion and adjusted EBITDA in the range of $174 million to $203 million." (CFO Schemm) "For the second quarter, we expect net sales in the range of $343 million to $365 million and adjusted EBITDA in the range of $32 million to $40 million." (CFO Schemm) "Our Q2 outlook reflects 2 dynamics" including "the delayed product launch at Marzocchi and the bike supplier disruption" and "lower F-150 unit volume in our upfit business due to the industry-wide aluminum supply disruption." (CFO Schemm) "Unlike the...
Earnings Call Insights: CytomX Therapeutics (CTMX) Q1 2026 Management View Dr. Sean McCarthy framed 2026 as “a transformational year for CytomX,” citing “excellent clinical progress with Varseta-M in late line colorectal cancer” and positioning Varseta-M as “the only EpCAM-directed ADC in clinical development to our knowledge.” Dr. McCarthy reiterated the company’s CRC ambition and timeline: “our ...
Earnings Call Insights: CytomX Therapeutics (CTMX) Q1 2026 Management View Dr. Sean McCarthy framed 2026 as “a transformational year for CytomX,” citing “excellent clinical progress with Varseta-M in late line colorectal cancer” and positioning Varseta-M as “the only EpCAM-directed ADC in clinical development to our knowledge.” Dr. McCarthy reiterated the company’s CRC ambition and timeline: “our goal is for Varseta to become a core component of the standard of care, including in earlier line therapy,” while noting it is “currently in dose optimization with the goal of advancing into a registrational study in late line CRC in the first half of 2027.” On the dataset scale and near-term catalyst, Dr. McCarthy said CytomX “completed enrollment in the ongoing dose optimization cohorts with 40 total patients” and “total enrollment across the Phase I study” is “113 patients,” adding the company “expect[s] to provide an overall Phase I data update… in the second half of this year.” On safety focus and mitigation, Dr. McCarthy highlighted diarrhea as “the principal adverse event of interest with Varseta,” and said updated strategies “have the potential to substantially reduce the rate of high-grade diarrhea we saw earlier,” adding, “Typically, patients respond very well to management and our overall discontinuation rates are low.” On expansion into earlier-line CRC, Dr. McCarthy said CytomX “initiated a combination with bevacizumab” and “expect initial clinical data for this combination by the first half of 2027,” and also said it “plan[s] to begin a Phase I/II chemotherapy combination study in the second half of 2026.” On pipeline breadth beyond CRC, Dr. McCarthy said the company is “on track to begin Phase I expansion cohorts in additional EpCAM-expressing indications in the second half of 2026,” with a goal of “Varseta’s ultimate pan-tumor potential.” On CX-801, Dr. McCarthy said CytomX “look[s] forward to sharing initial clinical data by the end of this year,” and descr...
Earnings Call Insights: Kontoor Brands (KTB) Q1 2026 Management view "This morning, we announced we have made the decision to divest the Lee brand as part of our strong commitment to maximize value." (President, CEO & Chair of the Board Scott Baxter) "By dedicating the entirety of Kontoor's resources and capital towards growth-oriented brands, we are confident we can meaningfully accelerate long-t...
Earnings Call Insights: Kontoor Brands (KTB) Q1 2026 Management view "This morning, we announced we have made the decision to divest the Lee brand as part of our strong commitment to maximize value." (President, CEO & Chair of the Board Scott Baxter) "By dedicating the entirety of Kontoor's resources and capital towards growth-oriented brands, we are confident we can meaningfully accelerate long-term growth and profitability while unlocking significant capital allocation optionality." (President, CEO & Chair of the Board Baxter) "This quarter is the 16th consecutive quarter of market share gains in men's and women's bottoms as measured by Circana." (President, CEO & Chair of the Board Baxter) "Through improved focus and increased investment capacity, we see a clear path to double-digit growth in our home market." (President, CEO & Chair of the Board Baxter) "We anticipate the primary use of proceeds from the divestiture of Lee will be used for accelerated share repurchases under our new $750 million authorization." (Executive VP, CFO & Global Head of Operations Joseph Alkire) Outlook "Full year revenue, including discontinued operations, is now expected to be in the range of $3.41 billion to $3.46 billion." (Executive VP, CFO & Global Head of Operations Alkire) "Revenue from continuing operations is now expected to be in the range of $2.66 billion to $2.71 billion, which has strengthened as compared to the assumptions embedded in our prior outlook." (Executive VP, CFO & Global Head of Operations Alkire) "Full year adjusted gross margin from continuing operations is expected to be in the range of 48.3% to 48.5%." (Executive VP, CFO & Global Head of Operations Alkire) "Adjusted operating income from continuing operations is expected to be in the range of $411 million to $418 million, including approximately $40 million of unmitigated expenses that have previously been allocated to the Lee business now reported in discontinued operations." (Executive VP, CFO & Global H...
Earnings Call Insights: Blend Labs (BLND) Q1 2026 Management View "We reported our Q1 numbers today... came in higher on revenue and non-GAAP operating income than expected" (CEO Nima Ghamsari). "We also signed 15 new deals and expansions in the quarter, including an eClose deal with a top-20 bank, along with a new mortgage deal with another top-100 bank" (CEO Ghamsari). "Our pipeline as of March ...
Earnings Call Insights: Blend Labs (BLND) Q1 2026 Management View "We reported our Q1 numbers today... came in higher on revenue and non-GAAP operating income than expected" (CEO Nima Ghamsari). "We also signed 15 new deals and expansions in the quarter, including an eClose deal with a top-20 bank, along with a new mortgage deal with another top-100 bank" (CEO Ghamsari). "Our pipeline as of March 31st is up more than 40% year-over-year" (CEO Ghamsari). "As of Monday, May 4th, 65 lenders have activated Autopilot, 22 are running it live in production and over 7,000 applications have already been touched by Autopilot since we moved to live production" (CEO Ghamsari). "Starting at the end of June, we're going to move to paid tiers" (CEO Ghamsari), and "over time, our intent is to move the paid tiers of Autopilot to a per funded loan model" (CEO Ghamsari). "Total revenue in the first quarter of 2026 was $30.8 million" and "non-GAAP operating income was $4.1 million" (Head of Finance and Administration Jason Ream). "We repurchased 11.2 million shares during the quarter at an average price of $1.66 per share... deploying $18.6 million of the $50 million authorization" (Head of Finance and Administration Ream). Outlook "For the second quarter of 2026, we expect total revenue to be between $32 million and $34 million" and "we expect Q2 non-GAAP operating income to be between $5.5 million and $6.5 million" (Head of Finance and Administration Ream). "We expect Mortgage Suite revenue to grow 4% to 10% year-over-year" and "we expect... economic value per funded loan... to be in the $79 to $80 range in Q2" (Head of Finance and Administration Ream). "We expect year-over-year Consumer Banking Suite revenue growth to be between negative 2% to positive 4% in Q2" (Head of Finance and Administration Ream). "In the absence of an uplift from Autopilot, which is too early to quantify and is not baked into any of our expectations" (Head of Finance and Administration Ream). Compared with la...
U.S. President Donald Trump. Photo: VCG A potential visit to China by U.S. President Donald Trump could yield significant developments regarding Middle East diplomacy and Washington’s stance on the Taiwan question, according to Gideon Rachman, chief foreign affairs columnist at the Financial Times. Speaking on May 7 local time at the second Caixin London Atlantic Dialogue, Rachman highlighted that...
U.S. President Donald Trump. Photo: VCG A potential visit to China by U.S. President Donald Trump could yield significant developments regarding Middle East diplomacy and Washington’s stance on the Taiwan question, according to Gideon Rachman, chief foreign affairs columnist at the Financial Times. Speaking on May 7 local time at the second Caixin London Atlantic Dialogue, Rachman highlighted that a key area to watch is whether a U.S.-China summit results in Beijing taking on a larger role in mediating the ongoing conflict between the U.S. and Iran.